ZENPEP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZENPEP (ZENPEP).
ZenPep (pancrelipase) is a pancreatic enzyme replacement therapy containing lipase, protease, and amylase. It hydrolyzes fats to monoglycerides, glycerol, and fatty acids; proteins to amino acids and peptides; and starch to dextrins and short-chain sugars, thereby facilitating digestion in patients with exocrine pancreatic insufficiency.
| Metabolism | Pancrelipase acts locally in the gastrointestinal tract and is not absorbed systemically in significant amounts; thus, it does not undergo hepatic metabolism via CYP450 enzymes. |
| Excretion | ZenPep (pancrelipase) is not absorbed systemically; it acts locally in the gastrointestinal tract. No significant systemic absorption occurs; therefore, excretion is primarily fecal as unabsorbed enzymes and degradation products. Renal excretion is negligible. |
| Half-life | Not applicable; ZenPep is not absorbed systemically and has no measurable plasma half-life. Clinical effect is directly related to local enzyme activity in the duodenum. |
| Protein binding | Not applicable; ZenPep is not absorbed systemically, so protein binding is irrelevant. The enzymes are proteins themselves but act locally. |
| Volume of Distribution | Not applicable; ZenPep is not absorbed, so Vd is not defined. |
| Bioavailability | Bioavailability is negligible (<1%) due to minimal systemic absorption; the drug acts locally in the gastrointestinal tract. |
| Onset of Action | Onset of action occurs within 30–60 minutes after oral administration, corresponding to the time required for the enteric-coated microspheres to dissolve in the duodenum and release active lipase, amylase, and protease. |
| Duration of Action | Duration of action is approximately 1–2 hours postprandially, correlating with the time enzymes remain active in the duodenum to digest nutrients. Dosing is typically with each meal or snack. |
| Molecular Weight | 50000 |
500 lipase units/kg per meal orally, with snacks at half the meal dose; maximum 2500 lipase units/kg per meal or 10,000 lipase units/kg per day.
| Dosage form | CAPSULE, DELAYED RELEASE |
| Renal impairment | Not required; ZenPep is not systemically absorbed. No dose adjustment based on GFR. |
| Liver impairment | No adjustment needed; ZenPep acts locally in the gastrointestinal tract without systemic absorption. |
| Pediatric use | Same weight-based dosing as adults: 500 lipase units/kg per meal, up to 2500 units/kg per meal; for infants, dose per 100 mL expressed milk or per feeding based on fat content. |
| Geriatric use | No specific dose adjustment; use lowest effective dose and monitor for gastrointestinal adverse effects. |
| 1st trimester | No evidence of fetal harm in animal studies; limited human data. |
| 2nd trimester | Considered safe; no known teratogenic effects. |
| 3rd trimester | Safe; used for maternal pancreatic insufficiency without known adverse fetal effects. |
Clinical note
Comprehensive clinical and safety monograph for ZENPEP (ZENPEP).
| Placental transfer | No significant placental transfer due to high molecular weight and protein nature; negligible. |
| Breastfeeding | Pancrelipase is a high molecular weight protein, unlikely to transfer into breast milk in significant amounts. Oral ingestion by infant would be inactivated in gastrointestinal tract. Considered compatible with breastfeeding. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to pork proteins or any component of the formulation
| Precautions | Fibrosing colonopathy reported, especially at high doses; do not exceed recommended dose, Potential for allergic reactions (e.g., anaphylaxis, urticaria) in patients with hypersensitivity to pork proteins, Risk of hyperuricemia, particularly with high doses; monitor uric acid levels if symptoms occur, Cases of rapid eye movement and abnormal behavior reported; monitor for signs, Potential for malnutrition if dosing is inadequate, Caution in patients with gout, renal impairment, or hyperuricemia |
| Food/Dietary | Avoid mixing capsule contents with alkaline foods (e.g., milk, yogurt, ice cream, custard) as they can dissolve the enteric coating prematurely. Administer with meals or snacks containing fat to maximize enzyme activity. No known interaction with alcohol or caffeine. Ensure adequate hydration with meals. |
Loading safety data…
| L1 (Safe) |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Based on mechanism of action (pancreatic enzymes), teratogenic risk is considered low; however, use only if clearly needed. |
| Fetal Monitoring | Standard prenatal care; no specific monitoring required beyond routine pregnancy management. |
| Fertility Effects | No known effects on fertility based on limited data; no studies on reproductive toxicity conducted. |
| Clinical Pearls | Zenpep (pancrelipase) is a pancreatic enzyme replacement therapy (PERT) used for exocrine pancreatic insufficiency. Capsules contain enteric-coated microspheres to protect enzymes from gastric acid. Administer with meals or snacks; do not crush or chew capsules. For patients unable to swallow capsules, open and sprinkle on soft acidic food like applesauce. Avoid mixing with alkaline foods (e.g., milk, ice cream) as enteric coating may dissolve prematurely. Monitor for symptoms of fibrosing colonopathy (rare) with high doses. Dose is based on lipase units; titrate to control steatorrhea. Assess for concurrent fat-soluble vitamin deficiencies. |
| Patient Advice | Take Zenpep exactly as prescribed with every meal or snack, usually 30 minutes before eating. · Swallow capsules whole; do not crush or chew. If you have trouble swallowing, open capsule and sprinkle contents on a small amount of soft, acidic food like applesauce or mashed bananas. Swallow immediately without chewing. · Do not mix capsule contents with milk, ice cream, or other dairy products as they may cause early enzyme release and mouth irritation. · Drink plenty of water after taking Zenpep. Avoid holding the medication in your mouth to prevent irritation. · Contact your doctor if you experience new abdominal pain, bloating, or changes in bowel habits, as these may indicate a rare but serious condition called fibrosing colonopathy. · Do not change dose or stop without consulting your doctor. Missed dose: skip if near next meal; do not double dose. · Store at room temperature away from moisture and heat. Keep out of reach of children. |